Inhibiting RRM2 to enhance the anticancer activity of chemotherapy

被引：95

作者：

Zhan, Yaqiong ^{[1
]}

Jiang, Lushun ^{[1
]}

Jin, Xuehang ^{[1
]}

Ying, Shuaibing ^{[1
]}

Wu, Zhe ^{[1
]}

Wang, Li ^{[2
]}

Yu, Wei ^{[1
]}

Tong, Jiepeng ^{[1
]}

Zhang, Li ^{[1
]}

Lou, Yan ^{[1
]}

Qiu, Yunqing ^{[1
]}

机构：

[1] Zhejiang Univ, Coll Med,State Key Lab Diag & Treatment Infect Di, Affiliated Hosp 1,Collaborat Innovat Ctr Diag & T, Natl Clin Res Ctr Infect Dis,Zhejiang Prov Key La, 79 QingChun Rd, Hangzhou 310000, Zhejiang, Peoples R China

[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Rehabil Med, 79 QingChun Rd, Hangzhou 310000, Zhejiang, Peoples R China

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2021年 / 133卷

基金：

中国国家自然科学基金;

关键词：

Ribonucleotide reductase subunit M2; Chemotherapy; Chemoresistance; Small interfering RNA; RRM2; inhibitors; Kinase inhibitors; RIBONUCLEOTIDE REDUCTASE M2; 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE 3-AP; ANTISENSE OLIGONUCLEOTIDE GTI-2040; MESSENGER-RNA EXPRESSION; BREAST-CANCER CELLS; PHASE-I TRIAL; NF-KAPPA-B; PANCREATIC-CANCER; DNA-DAMAGE; SUBUNIT M2;

D O I：

10.1016/j.biopha.2020.110996

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

RRM2, the small subunit of ribonucleotide reductase, is identified as a tumor promotor and therapeutic target. It is common to see the overexpression of RRM2 in chemo-resistant cancer cells and patients. RRM2 mediates the resistance of many chemotherapeutic drugs and could become the predictor for chemosensitivity and prognosis. Therefore, inhibition of RRM2 may be an effective means to enhance the anticancer activity of chemotherapy. This review tries to discuss the mechanisms of RRM2 overexpression and the role of RRM2 in resistance to chemotherapy. Additionally, we compile the studies on small interfering RNA targets RRM2, RRM2 inhibitors, kinase inhibitors, and other ways that could overcome the resistance of chemotherapy or exert synergistic anticancer activity with chemotherapy through the expression inhibition or the enzyme inactivation of RRM2.

引用

页数：8

共 97 条

[81] Furostanol and Spirostanol Saponins from Tribulus terrestris [J].

Wang, Zhen-Fang ;

Wang, Bing-Bing ;

Zhao, Yang ;

Wang, Fang-Xu ;

Sun, Yan ;

Guo, Rui-Jie ;

Song, Xin-Bo ;

Xin, Hai-Li ;

Sun, Xin-Guang .

MOLECULES, 2016, 21 (04)

[82] DRUG-SPECIFIC REARRANGEMENTS OF CHROMOSOME-12 IN HYDROXYUREA-RESISTANT MOUSE SEWA CELLS - SUPPORT FOR CHROMOSOMAL BREAKAGE MODEL OF GENE AMPLIFICATION [J].

WETTERGREN, Y ;

KULLBERG, A ;

LEVAN, G .

SOMATIC CELL AND MOLECULAR GENETICS, 1994, 20 (04) :267-285

[83] Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2) [J].

Xia, Guanggai ;

Wang, Hongcheng ;

Song, Ziliang ;

Meng, Qingcai ;

Huang, Xiuyan ;

Huang, Xinyu .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2017, 36 :107

[84] SiRNA-Mediated RRM2 Gene Silencing Combined with Cisplatin in the Treatment of Epithelial Ovarian Cancer In Vivo: An Experimental Study of Nude Mice [J].

Xue, Ting ;

Wang, Liming ;

Li, Yong ;

Song, Hao ;

Chu, Huijun ;

Yang, Hongjuan ;

Guo, Ailian ;

Jiao, Jinwen .

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2019, 16 (11) :1510-1516

[85] Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization [J].

Yan, Tao ;

Li, Hai-Ying ;

Wu, Jian-Song ;

Niu, Qiang ;

Duan, Wei-Hong ;

Han, Qing-Zeng ;

Ji, Wang-Ming ;

Zhang, Tao ;

Lv, Wei .

ONCOLOGY LETTERS, 2017, 14 (05) :5400-5408

[86] A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer [J].

Yen, Y ;

Margolin, K ;

Doroshow, J ;

Fishman, M ;

Johnson, B ;

Clairmont, C ;

Sullivan, D ;

Sznol, M .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (04) :331-342

[87] Small Interfering RNA (siRNA)-Mediated Silencing of the M2 Subunit of Ribonucleotide Reductase A Novel Therapeutic Strategy in Ovarian Cancer [J].

Zhang, Meng ;

Wang, Jing ;

Yao, RuYong ;

Wang, LiMing .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (04) :659-666

[88] Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response [J].

Zhang, Yong-Wei ;

Jones, Tamara L. ;

Martin, Scott E. ;

Caplen, Natasha J. ;

Pommier, Yves .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (27) :18085-18095

[89] Long noncoding RNA LINC00958 regulates cell sensitivity to radiotherapy through RRM2 by binding to microRNA-5095 in cervical cancer [J].

Zhao, Hui ;

Zheng, Guang-Hong ;

Li, Guang-Cai ;

Xin, Li ;

Wang, Yong-Sheng ;

Chen, Ying ;

Zheng, Xue-Mei .

JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (12) :23349-23359

[90] Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment [J].

Zhao, Xiao ;

Wang, Xiuchao ;

Sun, Wei ;

Cheng, Keman ;

Qin, Hao ;

Han, Xuexiang ;

Lin, Yu ;

Wang, Yongwei ;

Lang, Jiayan ;

Zhao, Ruifang ;

Zheng, Xiaowei ;

Zhao, Ying ;

Shi, Jian ;

Hao, Jihui ;

Miao, Qing Robert ;

Nie, Guangjun ;

Ren, He .

BIOMATERIALS, 2018, 158 :44-55

← 1 2 3 4 5 6 7 8 9 10 →